Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Use of Hydroxycobolamin in the Prevention of Vasoplegic Syndrome in Adult Patients Undergoing Cardiopulmonary Bypass
NCT06160219Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Aug 2019
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydroxocobalamin in vasoplegic syndrome (VPS) (2 arms), sponsored by Ain Shams University. Primary endpoint: Mean Arterial Pressure. Started Aug 2019; status: completed.
02
Drugs
hydroxocobalamin
03
Conditions
vasoplegic syndrome (VPS)
Beyond the preview
Go deeper on NCT06160219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160219.